# MEMORANDUM **To:** LumaBio Decision-Makers **From:** Counsel **Re:** PrecisionFill Packaging Line Dispute — Breach, Fraud, Acceptance, Damages, Setoff, and Settlement Strategy --- ## I. Executive Summary / Bottom Line LumaBio has a **plausible but not strong contract claim** and a **potentially strong fraud claim that is fact-sensitive and substantially weakened by the integration clause, no-reliance language, and LumaBio’s internal note**. The most important facts are: 1. **The line passed the contractual site-acceptance test**: 287 vials/min, 2.6% rejects, at 42% RH. 2. **LumaBio signed an acceptance certificate**, even if “subject to punch-list items and sustained production validation.” 3. **After the software patch, the line ran 286–289 vials/min**, occasionally reaching 300 briefly, but not sustaining 300. 4. **LumaBio used the line for eight months** and withheld the final $900,000. 5. The contract is likely **completely integrated**, contains a **no-reliance clause**, an **exclusive repair/replacement remedy**, a **purchase-price cap**, and a **consequential-damage exclusion**. 6. The pre-contract email and PrecisionFill’s internal chat create a **possible fraud claim**, especially because PrecisionFill appears to have known the line probably could not sustain 300 on LumaBio’s film. 7. LumaBio’s raw telemetry was overwritten after LumaBio said it was “considering all contractual and legal remedies,” but PrecisionFill likely acted **negligently, not intentionally**, so an **adverse inference is unlikely**; curative sanctions may be available if prejudice is shown. **Recommended course:** LumaBio should **not simply continue to withhold the $900,000 without a proper setoff notice**, and it should **not immediately litigate** on the contract claim alone. The best path is to: - Send a formal notice identifying specific breaches, calculating damages, and stating LumaBio’s intention to set off or deduct from the unpaid installment; - Demand preservation of telemetry and related records; - Place the $900,000 into escrow or pay it under a written setoff/credit claim, or negotiate a settlement in which LumaBio pays the final installment net of an agreed credit; - Use the fraud claim and the telemetry issue as leverage to obtain: - a monetary credit; - extended warranty/support; - engineering work, tuning, or feeder redesign to approach or achieve 300 vials/min under agreed conditions; - mutual releases. Litigation should be a **fallback**, not the first move, unless LumaBio obtains stronger evidence of reliance on the pre-contract email or the lost-customer damages are very large and well documented. --- # II. Contract Breach: Express Warranty and Other Contractual Obligations ## A. The “Rated Throughput: 300 Vials per Minute” Term The most important contract term is: > “Rated throughput: 300 vials per minute.” Under the Commercial Code, a factual affirmation, description, promise, model, or sample that becomes part of the basis of the bargain creates an express warranty. Formal words such as “warranty” are unnecessary. General praise or sales opinion does not create a warranty. ### LumaBio’s strongest contract argument LumaBio should argue that “rated throughput: 300 vials per minute” is a **technical specification** and therefore an express warranty that the line is capable of a 300-vial-per-minute throughput. The contract also warrants that the line will “conform to the written specifications and be free from defects in materials and workmanship.” If “rated throughput: 300” is a written specification, then a line that after patching only averages 286–289 vials/min, even if it occasionally reaches 300 for a few minutes, does not fully conform. This argument is strengthened by: - PrecisionFill’s factory test showing 302 vials/min using PrecisionFill’s film; - PrecisionFill’s internal chat indicating the architecture “probably tops out around 288” with LumaBio’s film unless redesigned; - the fact that even with compliant LumaBio film, the line “rarely exceeded 290.” ### PrecisionFill’s strongest response PrecisionFill will argue that “rated throughput” is not a guaranteed continuous operating speed, but a **nominal design rating**, while the actual contractual acceptance standard is the site-acceptance test: > four-hour test averaging at least 285 vials/min, with no more than 3% rejected units. That is a serious problem for LumaBio. The contract gives an **objective acceptance test at 285 vials/min**, not 300. The line passed that test: 287 vials/min and 2.6% rejects. PrecisionFill will also argue that: - “Rated throughput” is ambiguous; - the parties’ course of performance showed they treated 285+ as the operative acceptance level; - LumaBio signed an acceptance certificate; - LumaBio used the line for eight months; - after the software patch, the line ran 286–289, which is consistent with the acceptance standard and near, though not equal to, the 300 rating. ### Likely assessment The express-warranty claim is **viable but not strong**. It turns on whether “rated throughput: 300” is read as: 1. a guaranteed performance specification; or 2. a nominal capacity rating qualified by the 285 acceptance test. The written acceptance standard and LumaBio’s acceptance certificate favor PrecisionFill. The internal chat and post-patch performance below 300 favor LumaBio. A court would likely treat this as a fact-intensive interpretation question. LumaBio should not assume it has a clear breach-of-contract claim for failure to reach 300. --- ## B. Feed-Control Software Problem as Defect in Materials or Workmanship The contract also warrants that the line is “free from defects in materials and workmanship.” The feed-control software problem that caused the line to average only 270 vials/min after the humidity issue was fixed likely qualifies as a defect in workmanship or design, assuming the software was part of the delivered system. However, PrecisionFill delivered a patch six weeks later. After the patch, the line averaged 286–289 vials/min. If the contractual standard is 285, PrecisionFill can argue the defect was cured. If the contractual standard is 300, LumaBio can argue the cure was ineffective because the line still did not sustain 300. Again, the decisive issue is interpretation: **Was the contractual performance standard 285 or 300?** --- ## C. Humidity and Film Variance: Buyer-Caused Nonconformity PrecisionFill has two strong defenses based on LumaBio’s own facility and film. ### 1. Humidity The contract required the site-acceptance test to occur at **35–45% relative humidity**. The acceptance test was at 42% RH and passed. But during the next three weeks, humidity ranged from **52–60% RH** because LumaBio’s HVAC project was incomplete. During that period, the line averaged only 238–260 vials/min and repeatedly jammed. PrecisionFill’s technician blamed humidity. This period is largely not useful to LumaBio. PrecisionFill will argue that the contract did not require the line to perform outside the agreed humidity range, and LumaBio caused or at least failed to cure the out-of-range conditions. After HVAC was repaired, humidity was 39–43%, within the contract range. But the line then averaged only 270 vials/min until the software patch. That post-HVAC, pre-patch period is more important to LumaBio because the humidity defense is weaker there. ### 2. Film Variance The contract required use of LumaBio’s packaging film **provided the film met Schedule B variance specifications**. Approximately 18% of LumaBio’s film lots exceeded the permitted thickness variance. LumaBio possessed pre-contract quality-control data showing some lots exceeded the limits, but did not give that data to PrecisionFill. The line performed worse when those lots were used, though even with compliant lots it rarely exceeded 290. PrecisionFill will argue: - LumaBio failed to provide conforming film for a significant portion of production; - LumaBio failed to disclose known film-quality data; - performance problems during runs using nonconforming film are not PrecisionFill’s responsibility; - LumaBio’s film issue may explain part of the performance gap. LumaBio’s counter is that even with compliant film, the line still did not reach 300, and PrecisionFill’s internal chat suggested the architecture with LumaBio’s film “probably tops out around 288 unless we redesign the feeder.” ### Assessment The humidity and film-variance defenses are strong for PrecisionFill, especially for early poor performance and some of LumaBio’s cost claims. They do not completely eliminate the 300-throughput issue, because the line still did not reach 300 even with compliant film. But they significantly weaken LumaBio’s damages claim and any claim that the line failed to meet the 285 acceptance standard. --- # III. The Pre-Contract Email: Admissibility and Fraud The vice president emailed: > “This line will run 300 all day in your facility on your current film. If it cannot, we will take it back and make you whole.” LumaBio’s project leader then wrote internally: > “Their contract only guarantees a 285 acceptance test. We should add the 300 commitment, but procurement wants this signed today.” No change was made. ## A. Admissibility to Prove Contract Terms The contract states that the writing is the complete agreement and that LumaBio did not rely on statements not contained in the contract. Under the given Commercial Code rules, a completely integrated written agreement excludes prior or contemporaneous agreements that contradict it. The email likely contradicts the written agreement because: - the written acceptance test is 285, not 300; - the written remedy is repair or replacement, not “take it back and make you whole”; - the written agreement contains disclaimers, limitations, and a no-reliance clause; - LumaBio itself stated it did not rely on outside statements. Therefore, the email is likely **not admissible to create a separate contractual warranty** or to vary the written agreement. It probably does not make the contract require sustained 300 vials/min. That said, the email may still be relevant for: - fraud; - scienter; - state of mind; - possible interpretation if the writing is found only partially integrated or ambiguous; - course of performance or waiver, though the integration clause makes that less clean. ## B. The Email as Fraud This is LumaBio’s strongest potential claim. Fraud requires: 1. a material false statement of present or past fact; 2. knowledge or reckless disregard of falsity; 3. intent to induce reliance; 4. reasonable reliance; 5. resulting loss. A promise about future performance is actionable only if the speaker had **no present intention to perform** or **misrepresented an existing technical capability**. ### 1. False statement / misrepresentation of existing capability The statement, “This line will run 300 all day in your facility on your current film,” is primarily a promise about future performance. But it is actionable if PrecisionFill misrepresented an existing technical capability or had no present intention to perform. The internal chat is very helpful to LumaBio: > “Sales keeps telling them 300. With their film, this architecture probably tops out around 288 unless we redesign the feeder.” And: > “Three hundred is technically possible with perfect film and enough tuning. Do not put 288 in writing.” This suggests PrecisionFill knew, or recklessly disregarded, that the line probably could not sustain 300 on LumaBio’s film without redesign. The statement “Do not put 288 in writing” also suggests an intent to keep the limitation out of the contractual record. ### 2. Knowledge or reckless disregard PrecisionFill’s engineers knew, before signing, that the architecture likely topped out around 288 with LumaBio’s film. That supports knowledge or reckless disregard of the falsity of the “300 all day” statement. ### 3. Intent to induce reliance The vice president’s email was sent before signing and appears intended to close the deal or reassure LumaBio about performance. “Sales keeps telling them 300” suggests a pattern of representations intended to induce LumaBio’s commitment. ### 4. Reasonable reliance — the weakest element for LumaBio This is the major obstacle. PrecisionFill will argue: - the contract was complete and integrated; - LumaBio expressly stated it did not rely on statements not in the contract; - LumaBio’s own project leader wrote that the contract “only guarantees a 285 acceptance test”; - LumaBio knew it should add the 300 commitment but did not; - LumaBio is a sophisticated commercial party; - therefore, reliance on the oral/email promise was unreasonable. The no-reliance clause does not automatically defeat fraud under the given rules, but it is highly relevant to reasonable reliance. LumaBio’s response is that: - reliance can be on the truth of the technical representation, not merely on a contractual promise; - the representation concerned information peculiarly within PrecisionFill’s knowledge; - LumaBio’s internal note shows that 300 throughput was material; - LumaBio may have relied on the VP’s statement in deciding to proceed without adding extra contractual protection; - the merger/no-reliance language does not bar a claim based on an intentionally false factual representation concerning PrecisionFill’s technical capability. Still, the internal note is dangerous for LumaBio. It may allow a court or jury to conclude that LumaBio knew the contract only guaranteed 285 and chose not to protect itself, undermining reasonable reliance. ### 5. Resulting loss If fraud is proven, LumaBio could claim the losses caused by reliance, potentially including lost-customer damages and other consequential losses, because the contract’s liability limitations do not apply to fraud. But LumaBio must prove causation and reasonable certainty. It must show that, but for the false statement, it would not have signed, accepted, or incurred the losses in the same way. ### Likely assessment The fraud claim is **potentially strong on scienter and intent**, but **uncertain on reasonable reliance**. It is LumaBio’s best leverage, but not a guaranteed win. --- # IV. Significance of the 285 Acceptance Standard, the 300 Rating, the Certificate, and Subsequent Conduct ## A. The 285 Acceptance Standard The contract required a four-hour test averaging at least 285 vials/min and no more than 3% rejects. The line achieved 287 vials/min and 2.6% rejects at 42% RH. This is PrecisionFill’s best factual defense. It shows that the line met the only objective site-acceptance test in the contract. LumaBio cannot easily argue that the line failed acceptance. The acceptance test was not 300. It was 285. ## B. The 300 Rated-Throughput Term The 300 term is important, but ambiguous. It may be a performance specification, a design rating, or a nominal capacity. The acceptance test at 285 suggests the parties built in a practical acceptance margin below the rated number. LumaBio’s best interpretation: - 300 is a written specification; - the line warranted to conform to written specifications; - the line should be capable of 300; - the 285 test is a minimum acceptance floor, not a ceiling. PrecisionFill’s best interpretation: - 300 is the rated or nominal throughput; - the contract’s actual acceptance standard is 285; - the line passed acceptance; - post-patch performance of 286–289 is consistent with the contractual standard. ## C. The Acceptance Certificate LumaBio signed: > “Site acceptance completed, subject to punch-list items and sustained production validation.” This is a significant problem for LumaBio. The certificate says “site acceptance completed.” That likely signifies acceptance under the Code. The “subject to” language is ambiguous. It may mean: 1. acceptance was subject to completion of punch-list items; or 2. acceptance was conditional on sustained production validation; or 3. the certificate accepted the line while preserving post-acceptance work items. The certificate did not identify the sustained-production criteria. That omission hurts LumaBio. If LumaBio intended to preserve a 300-vial-per-minute claim, it should have identified that criteria. PrecisionFill will argue that LumaBio accepted the line and cannot now reject it. LumaBio can argue that the certificate preserved a validation issue, but that is a weaker position because the contract’s own validation/acceptance standard was 285. ## D. Parties’ Subsequent Conduct Subsequent conduct may explain ambiguous terms and may support waiver. LumaBio’s conduct: - signed acceptance; - used the line for eight months; - did not clearly revoke; - withheld final payment; - continued ordinary production. PrecisionFill’s conduct: - sent technicians from the first week; - identified a software problem; - delivered a patch six weeks later; - achieved 286–289 after patch. This conduct supports PrecisionFill’s argument that the parties treated 285+ as acceptable and that any 300 issue was not treated as a fundamental rejection-level breach. It also supports PrecisionFill’s argument that the line was repaired to the contractual acceptance standard. For LumaBio, the conduct shows: - PrecisionFill knew early about the performance issue; - the software problem was real; - the line still did not reach 300 after patch; - PrecisionFill did not offer redesign or replacement. But conduct is more useful to LumaBio for fraud and notice than for establishing a clear contract right to reject or revoke. --- # V. Could LumaBio Reject or Revoke Acceptance? ## A. Rejection A buyer may reject goods if they fail to conform, provided rejection is effective and timely. LumaBio did not effectively reject. It signed a certificate stating site acceptance was completed. Even if the certificate was “subject to punch-list items and sustained production validation,” the words “site acceptance completed” strongly indicate acceptance. Also, if the contractual standard was 285, the line conformed. If the standard was 300, LumaBio still accepted rather than rejecting. Therefore, LumaBio likely **cannot reject**. ## B. Revocation A buyer may revoke acceptance only if: 1. the nonconformity substantially impairs the goods’ value; and 2. the original acceptance was reasonably induced by: - difficulty discovering the defect, or - the seller’s assurances; and 3. revocation occurs within a reasonable time; and 4. there has not been a substantial change not caused by the defect. ### 1. Substantial impairment The software defect caused a period in which the line averaged 270 after the HVAC repair and before the patch. That could support substantial impairment, especially if LumaBio needed 300 for a major customer. But after the patch, the line ran 286–289, above the 285 acceptance standard. That weakens the claim that the goods’ value was substantially impaired under the contractual standard. If LumaBio’s theory is failure to reach 300, then the impairment may be substantial. But the contract’s objective acceptance standard was 285, which makes that harder. ### 2. Difficulty discovering the defect or seller’s assurances The software problem may not have been obvious. LumaBio accepted after a passing test and only later discovered the issue. The VP’s email may also be an assurance. This element favors LumaBio in the abstract. ### 3. Reasonable time LumaBio used the line for eight months and withheld the final installment. There is no clear fact showing a timely, express revocation. A breach notice is not necessarily a revocation. This is a serious problem. ### 4. Continued use Continued use after attempted revocation may undermine revocation, although limited use necessary to avoid serious loss does not automatically defeat it. LumaBio used the line for eight months. It may argue that continued use was necessary to avoid serious loss, especially if the line was already installed and production was ongoing. But eight months of ordinary production is a long time and will be viewed unfavorably. ### Assessment LumaBio likely **cannot revoke acceptance**. The strongest obstacles are: - signed acceptance certificate; - no clear timely revocation; - continued use for eight months; - post-patch performance above 285; - buyer-caused humidity and film issues during part of the period. --- # VI. Was Notice Timely? The buyer must notify the seller of breach within a reasonable time after discovering or when it should have discovered the breach. Actual seller knowledge may affect whether formal notice was sufficient. LumaBio first sent a formal breach notice 75 days after sustained production began. PrecisionFill’s technicians had been working on the performance problem since the first week. ### LumaBio’s position Notice was timely, or at least not fatal, because: - PrecisionFill knew about the performance problem from the first week; - PrecisionFill’s technicians were working on it; - LumaBio sent an email on day 25 stating it was “considering all contractual and legal remedies”; - the problem involved software and required diagnostic work; - 75 days after sustained production is not unreasonable under the circumstances. ### PrecisionFill’s position PrecisionFill may argue: - if the breach was failure to meet 300, LumaBio knew at acceptance because the test showed 287; - if the breach was the software defect, LumaBio should have discovered it sooner; - LumaBio continued use for eight months without clear notice of breach or setoff. ### Assessment Because PrecisionFill had actual knowledge through its technicians, LumaBio’s notice is likely **sufficient or at least not barred**. However, LumaBio should now send a clear, specific notice identifying the breach, the damages, and the intention to set off. The earlier notice may have been too general or may not have expressly stated LumaBio’s intention to deduct from the final installment. --- # VII. Did the Exclusive Repair or Replacement Remedy Fail of Its Essential Purpose? The contract makes repair or replacement the exclusive remedy. Under the Code, an exclusive repair or replacement remedy fails of its essential purpose if the seller cannot or will not provide an effective cure within a reasonable time. ### If the contractual standard is 285 PrecisionFill will argue the remedy did not fail because: - the line passed the 285 acceptance test; - after the software patch, it ran 286–289; - the defect was cured within six weeks; - six weeks is a reasonable time for a software patch. ### If the contractual standard is 300 LumaBio will argue the remedy failed because: - the patch did not produce sustained 300; - ordinary production remained 286–289; - PrecisionFill did not offer redesign of the feeder; - PrecisionFill did not offer replacement; - the only cure did not restore the warranted rated throughput. ### Assessment The remedy likely **failed only if 300 is treated as a guaranteed performance specification**. If 285 is the operative standard, the repair likely succeeded. Even if the exclusive remedy failed, the consequential-damage exclusion may still apply. The contract expressly states that the consequential-damage exclusion remains effective even if the exclusive remedy fails. Under the given rules, a separate exclusion of consequential damages remains enforceable unless unconscionable or expressly made dependent on the exclusive remedy. Here, the exclusion is not made dependent on the exclusive remedy, and it likely would be enforceable between sophisticated commercial parties. Therefore, even if the exclusive remedy failed, LumaBio would likely still be barred from most consequential damages under the contract. --- # VIII. Damages: What Is Recoverable? ## A. Direct Contract Damages Direct damages may include the difference between the value promised and the value delivered. If LumaBio can prove the line warranted a sustained 300-vial throughput and delivered only 286–289, it may claim a diminution in value. But the amount is likely modest, perhaps a few percent of the $4.8 million price, subject to proof. It is unlikely to equal the full $900,000 withheld without additional evidence. PrecisionFill will argue the line delivered what the contract accepted: at least 285 vials/min. In that case, direct damages are minimal or zero. ## B. Overtime, Temporary Labor, and Expedited Shipping These costs may be claimed as incidental or consequential damages. ### Contract claim LumaBio may argue some costs were reasonable expenses incurred in dealing with the nonconformity. But PrecisionFill will argue they are consequential, especially if they were incurred to maintain production or compensate for lost throughput. The contract excludes: > lost profits, lost production, customer penalties, or other consequential damages. Overtime and temporary labor used to keep production running are likely to be characterized as lost production or consequential damages. Expedited shipping may also be consequential if it was used to compensate for lost production or to meet customer deadlines. Some expenses might be treated as incidental if they were directly related to inspection, receipt, transportation, care, or custody of the goods. But based on the facts given, most of these costs are likely to fall within the consequential-damage exclusion. ### Fraud claim If fraud is proven, the contract’s liability limitations do not apply to fraud. Then LumaBio could potentially recover overtime, temporary labor, expedited shipping, and lost-customer losses, subject to causation, reasonable certainty, and mitigation. ## C. Lost Customer Order / Lost Profits Under the contract, lost-customer and lost-profit damages are expressly excluded. PrecisionFill knew LumaBio intended to use the line for the customer, but the express exclusion is strong. Contractually, lost-customer damages are likely **not recoverable**. If fraud is proven, the exclusion may not apply. LumaBio could then argue: - PrecisionFill knew the customer; - the false statement induced LumaBio to proceed; - the customer loss was a direct result of the line’s inability to perform as represented. But LumaBio must prove: - reliance on the false statement; - that the customer loss was caused by PrecisionFill’s misrepresentation; - reasonable certainty of the profit; - mitigation. ## D. Cap and Limitations PrecisionFill’s total liability is capped at the purchase price, and consequential damages are excluded. Those limitations do not apply to fraud, gross negligence, or willful misconduct. If no fraud or gross negligence is found, LumaBio is limited to: - direct damages; - possibly some incidental damages, if not excluded; - no lost profits; - no lost customer; - cap of $4.8 million, though that cap may not be reached. If fraud is found, the cap and consequential-damage exclusion likely fall away. --- # IX. Did LumaBio Properly Withhold the Final $900,000? The buyer may deduct damages from an unpaid price after notifying the seller of its intention to do so. The facts say LumaBio withheld the final $900,000 and used the line for eight months. It first sent a formal breach notice 75 days after sustained production began. It is not clear that LumaBio gave a specific notice of its intention to deduct before withholding, or that the withheld amount was a good-faith estimate of damages. ### Risks If LumaBio withheld $900,000 without proper notice, or if its actual damages are less than $900,000, PrecisionFill may have a claim for nonpayment. LumaBio’s defenses would be: - good faith dispute; - setoff for breach; - failure of exclusive remedy; - fraud. But a court may not allow a buyer to withhold the entire remaining installment if the proven contract damages are much smaller. ### Better approach LumaBio should either: 1. send a specific setoff notice identifying the breach and the amount it intends to deduct; or 2. place the $900,000 in escrow; or 3. pay the amount under protest with a written claim for credit. If LumaBio wants to preserve maximum leverage, **escrow** is often the safest financial position. It removes PrecisionFill’s claim that LumaBio simply stopped paying, while preserving LumaBio’s setoff and fraud claims. --- # X. Deleted Telemetry: Sanctions or Adverse Inference? PrecisionFill’s system automatically overwrote raw diagnostic telemetry after 30 days. LumaBio sent an email on day 25 saying it was “considering all contractual and legal remedies.” The raw telemetry was overwritten on day 30. PrecisionFill preserved summary reports but did not suspend automatic deletion. ## A. Duty to Preserve A party must preserve relevant evidence when litigation is reasonably anticipated. LumaBio’s day-25 email likely made litigation reasonably anticipated, at least as to the performance dispute. PrecisionFill controlled the raw telemetry and knew or should have known it was relevant. Therefore, PrecisionFill likely had a duty to preserve the raw telemetry after day 25. ## B. Negligence vs. Intent The automatic overwrite suggests negligence rather than intentional destruction. PrecisionFill preserved summary reports but did not suspend deletion. That may be careless or negligent, but it does not clearly show intent to deprive LumaBio of the evidence. Under the given rules, an adverse inference requires **intent to deprive** the opposing party of the evidence. That is a high bar. Based on the facts given, LumaBio should not expect an adverse inference merely because the raw telemetry was automatically deleted after LumaBio’s email. ## C. Available Sanctions If LumaBio can show prejudice, the court may order measures that cure the prejudice. Examples: - prohibit PrecisionFill from using the missing raw telemetry to disprove LumaBio’s claims; - limit PrecisionFill’s arguments about the missing raw data; - require PrecisionFill to produce all summary reports, logs, metadata, and related records; - shift some costs to PrecisionFill for LumaBio’s increased burden of proof; - instruct the jury that the missing raw telemetry may not be used against LumaBio. But an adverse inference that the missing data would have been unfavorable to PrecisionFill is unlikely unless LumaBio can show PrecisionFill intentionally destroyed or withheld the data. ## D. Practical implication The telemetry issue is useful, but not decisive. LumaBio should: - demand immediate preservation of all telemetry-related records; - demand suspension of any automatic deletion; - request production of summary reports and metadata; - preserve its own performance, humidity, and film-quality data; - use the issue as leverage in settlement discussions. --- # XI. Strongest Defenses PrecisionFill Will Assert ## A. Humidity Defense PrecisionFill’s strongest factual defense is that the line was tested and operated outside the contractual humidity range during the worst early performance period. The contract required 35–45% RH for the test. LumaBio’s facility ran at 52–60% RH because its HVAC project was incomplete. This defense is strong for the first three weeks and may reduce or eliminate damages attributable to that period. LumaBio’s counter is that after the HVAC repair, the line still averaged only 270 until the software patch. ## B. Film-Variance Defense PrecisionFill will argue that LumaBio used film lots that did not meet Schedule B, and that LumaBio knew or should have known from pre-contract quality-control data. The line performed worse with those lots. This defense is strong to the extent LumaBio used nonconforming film and did not disclose the data. LumaBio’s counter is that even with compliant lots, the line rarely exceeded 290 and did not reach 300. ## C. Contract-Language Defense PrecisionFill will lean heavily on: - the 285 acceptance test; - the acceptance certificate; - the integration clause; - the no-reliance clause; - the disclaimers; - the exclusive repair/replacement remedy; - the consequential-damage exclusion; - the liability cap; - the ambiguity of “rated throughput.” This is likely PrecisionFill’s strongest overall defense. It argues that the parties bargained for a 285 acceptance standard, not a guaranteed 300-vial performance level. ## D. Reliance Defense For fraud, PrecisionFill will argue LumaBio did not reasonably rely on the email because: - the contract was integrated; - LumaBio stated it did not rely on outside statements; - LumaBio’s project leader wrote that the contract only guaranteed 285; - LumaBio chose not to add the 300 commitment; - LumaBio is sophisticated. This is a serious defense, but not automatic. ## E. Causation Defense PrecisionFill will argue that LumaBio’s losses were caused by: - LumaBio’s incomplete HVAC; - nonconforming film lots; - LumaBio’s failure to disclose film data; - LumaBio’s continued use of the line; - market or customer-specific factors. For lost-customer damages, PrecisionFill will argue the loss was too speculative or not caused by any contractual breach. ## F. Mitigation Defense PrecisionFill will argue LumaBio failed to mitigate by: - continuing to use the line for eight months; - not rejecting or revoking earlier; - not maintaining contract humidity; - not ensuring film compliance; - not giving clear setoff notice; - not seeking alternative production arrangements. LumaBio can respond that it used the line to avoid greater loss and that it pursued PrecisionFill’s technicians from the beginning. But mitigation remains a live issue. --- # XII. Strategic Recommendation: Litigate, Pay, Demand Engineering, or Settle? ## A. Do Not Litigate Immediately as the First Step A contract-only lawsuit is risky. PrecisionFill has strong defenses based on acceptance, the 285 standard, humidity, film variance, and the written limitations. If LumaBio sues only for breach of contract, PrecisionFill may counterclaim for the $900,000, and LumaBio may end up paying interest or costs. Litigation could still be appropriate if: - the lost-customer loss is very large; - LumaBio has strong evidence of reliance on the VP’s email; - discovery is likely to produce the internal chat and related communications; - LumaBio is willing to risk the contract defenses to pursue the fraud claim. But litigation is better used as a **leverage tool** after proper notice and preservation demands. ## B. Do Not Simply Pay and Walk Away Paying the full $900,000 without a settlement or setoff would give PrecisionFill final payment and may reduce its incentive to provide credit, extended support, or engineering work. However, LumaBio should not continue naked withholding either, because that exposes LumaBio to a nonpayment claim. The best financial posture is usually: - pay into escrow; or - pay with a written setoff/credit claim; or - negotiate a settlement in which payment is net of an agreed credit. ## C. Demand Additional Engineering Work as Part of a Package A standalone demand for additional engineering work is legally weak unless LumaBio can prove the line warranted sustained 300 and the exclusive remedy failed. But as a **commercial settlement item**, it is reasonable. LumaBio should seek: - feeder redesign, tuning, or software optimization; - performance testing under agreed humidity and film conditions; - extended warranty; - spare parts and support; - a monetary credit for documented direct/incidental losses. This converts a weak contract claim into a practical commercial solution. ## D. Recommended Resolution: Negotiate a Commercial Settlement The strongest course is to negotiate. ### Proposed settlement structure LumaBio could propose: 1. **Payment mechanics** - LumaBio places the $900,000 in escrow, or pays it net of an agreed credit. - The escrow is released to PrecisionFill only after settlement terms are satisfied, or it is released net of a credit. 2. **Monetary credit** - PrecisionFill provides a credit for verified direct and incidental losses, or a negotiated settlement amount. - The credit should be supported by documentation of overtime, temporary labor, expedited shipping, downtime, and any direct diminution in value. 3. **Engineering and performance support** - PrecisionFill performs additional tuning, feeder work, or software optimization at its cost. - The goal is to bring the line closer to 300 vials/min under agreed conditions. - The settlement should specify: - acceptable humidity range; - compliant film requirements; - test protocol; - performance target; - cure period; - remedy if the target is not met. 4. **Warranty and support** - Extended warranty from the date of final patch or settlement. - Spare parts. - Priority support. - Training if needed. 5. **Releases** - Mutual release of known claims. - Ideally, LumaBio should not release the fraud claim without receiving meaningful consideration. - If LumaBio believes the fraud claim is strong and the lost-customer loss is large, it should not release fraud for only a small credit. 6. **Preservation and confidentiality** - Immediate litigation hold and preservation of telemetry, summaries, design documents, and communications. - Confidentiality of settlement terms. ### Why settlement is best - LumaBio avoids the risk of a judgment for nonpayment. - PrecisionFill avoids fraud exposure. - LumaBio gets practical value: money, support, and performance improvement. - The dispute is resolved without expensive discovery. - LumaBio can continue using the line with better support. --- # XIII. Recommended Next Steps LumaBio should act promptly on the following: ## 1. Send a formal notice The notice should: - identify the specific contractual terms at issue; - state the line’s performance history; - identify the software defect and failure to achieve sustained 300, if LumaBio is asserting that theory; - state that LumaBio is treating the exclusive remedy as failed, if appropriate; - calculate or estimate damages; - expressly state LumaBio’s intention to set off or deduct from the final installment; - demand cure within a reasonable time; - reserve all rights, including fraud; - demand preservation of all telemetry, summary reports, logs, metadata, engineering files, and internal communications. ## 2. Demand preservation LumaBio should specifically demand that PrecisionFill: - suspend automatic deletion of raw telemetry; - preserve summary reports; - preserve humidity and performance logs; - preserve film test data; - preserve engineering design and software patch records; - preserve internal communications about throughput, film, and performance. ## 3. Preserve LumaBio’s own evidence LumaBio should preserve: - acceptance certificate; - performance logs; - humidity data; - HVAC records; - film lot quality-control data; - rejected-unit data; - overtime and labor records; - expedited shipping invoices; - customer order documentation; - lost-profit analysis; - internal emails, including the project leader’s note; - communications with PrecisionFill. ## 4. Evaluate the fraud claim carefully Before making a strong settlement demand, LumaBio should assess: - the size of the lost customer order; - whether the loss is documented with reasonable certainty; - whether LumaBio can show it relied on the VP’s statement; - whether the project leader’s internal note fatally undermines reliance; - whether the internal chat can be obtained through discovery if litigation is filed. If the lost-customer loss is very large and reliance is credible, the fraud claim becomes much more valuable. ## 5. Escrow or pay under a written setoff claim LumaBio should avoid continuing to withhold the full $900,000 without a proper setoff notice. The safest option is escrow. If settlement is imminent, a negotiated net payment may be acceptable. ## 6. Use litigation only if settlement fails If PrecisionFill refuses a reasonable settlement, LumaBio can consider filing suit or answering PrecisionFill’s payment suit. The claims should include: - breach of express warranty, if asserting the 300-throughput specification; - breach of warranty for defects in materials/workmanship; - failure of the exclusive remedy, if applicable; - setoff against the final installment; - fraud based on the pre-contract email and internal technical knowledge; - possible gross negligence or willful misconduct, depending on evidence. But LumaBio should proceed with litigation only after protecting its payment exposure through escrow or a written setoff arrangement. --- # XIV. Final Conclusion LumaBio’s strongest legal theory is **fraud**, not ordinary contract breach. The contract claim is weakened by the 285 acceptance standard, the acceptance certificate, continued use, humidity and film issues, and the written limitations. The fraud claim is strengthened by the VP’s email and PrecisionFill’s internal chat, but it is weakened by the integration clause, no-reliance language, and LumaBio’s internal note. The deleted telemetry is useful but probably not enough to support an adverse inference without evidence of intent. It may support curative sanctions if prejudice is shown. LumaBio should not simply pay the final installment without protection, nor should it simply continue withholding it. The best course is to **negotiate a commercial settlement**, using the fraud claim and the telemetry issue as leverage, while placing the $900,000 in escrow or paying it under a written setoff/credit arrangement. LumaBio should seek a monetary credit, extended warranty, and engineering work to improve throughput, and should reserve or carefully evaluate the fraud claim before releasing it.